Skip to content
OpenCapital
Get started
Corcept Therapeutics logo

Corcept Therapeutics (CORT) Q1 2026 Earnings

CORT·Reported April 30, 2026·After market close

Corcept Therapeutics reported Q1 2026 revenue of $164.9M (+4.9% YoY), missed analyst consensus of $185.8M by $20.9M. Diluted EPS came in at $-0.30, missed the $-0.14 consensus by $0.16.

Revenue
$164.9Mmissed by $20.9M
Consensus: $185.8M
Diluted EPS
$-0.30missed by $0.16
Consensus: $-0.14
SEC

SEC Filings

Earnings release8-K · 0001628280-26-028892
Quarterly report10-Q · 0001628280-26-028902

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Corcept Therapeutics's Q1 2026 earnings report.

Corcept Therapeutics (CORT) reported Q1 2026 earnings on April 30, 2026 after market close.

Corcept Therapeutics reported revenue of $164.9M and diluted EPS of $-0.30 for Q1 2026.

Revenue missed the consensus estimate of $185.8M by $20.9M. EPS missed the consensus estimate of $-0.14 by $0.16.

Compared to the same quarter a year prior, revenue grew 4.9% from $157.2M a year earlier.

You can read the 8-K earnings release (0001628280-26-028892) and the 10-Q periodic report (0001628280-26-028902) directly on SEC EDGAR. The filing index links above go to sec.gov.